Free Newsletter
Vaccine research heads to outer space
A program to develop a new salmonella vaccine has headed to the outer limits. The space shuttle Discovery is carrying a test strain of salmonella, and officials at Spacehab are using the experiment to highlight plans for an ambitious biotech space program.
A vaccine to protect people from salmonella poisoning has never been developed, at least in part because its virulence dissipates quickly. In microgravity, however, the potency of salmonella is tripled, giving researchers a chance to genetically engineer a strain that can be used in a vaccine. And Spacehab will advance its biotech work in a national laboratory on the International Space Station.
"You need a facility where you can study the effect of microgravity" on biological systems, said John Uri, NASA deputy manager of the ISS payloads office.
- read the story from AFP
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: